Literature DB >> 21329416

A no-reflow prediction model in patients with ST-elevation acute myocardial infarction and primary drug-eluting stenting.

Chang-Hua Wang1, Yun-Dai Chen, Xin-Chun Yang, Le-Feng Wang, Hong-Shi Wang, Zhi-Jun Sun, Hong-Bin Liu.   

Abstract

OBJECTIVES: This study was undertaken to assess independent no-reflow predictors in patients with ST-elevation acute myocardial infarction (STEMI) and primary drug-eluting stenting in the current interventional strategies.
DESIGN: One thousand four hundred and thirteen patients with STEMI were successfully treated with primary drug-eluting stenting within 12 h after AMI. All clinical, angiographic and procedural data were collected. Univariate and multivariate logistic regression was used to identify independent no-reflow predictors.
RESULTS: The no-reflow was found in 297 (21%) of 1413 patients. Univariate and multivariate logistic regression identified that age (>65 years, OR 1.47, 95% CI 1.46-1.49; p = 0.007), long time-to-reperfusion (>6 h, OR 1.27, 95% CI 1.16-1.40; p = 0.001), admission plasma glucose (>13.0 mmol/L, OR 1.27, 95% CI 1.16-1.40; p = 0.027), collateral circulation (0-1, OR 1.69, 95% CI 1.25-2.29; p = 0.001), pre-PCI thrombus score (≥4, OR 1.36, 95% CI 1.16-1.79; p = 0.011), and IABP use before PCI (OR 2.89, 95% CI 1.65-5.05; p < 0.0001) were independent no-reflow predictors. The no-reflow rate significantly increased as the number of independent predictors increased (0%, 6%, 15%, 25%, 40%, 50% and 100% in patients with 0, 1, 2, 3, 4, 5, and 6 independent predictors, respectively; p < 0.0001).
CONCLUSIONS: The prediction model consisted of six no-reflow predictors in patients with STEMI and primary drug-eluting stenting and should be confirmed in large-scale prospective studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21329416     DOI: 10.3109/14017431.2011.558209

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  6 in total

1.  Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention.

Authors:  Hua Zhou; Xiao-Yan He; Shao-Wei Zhuang; Juan Wang; Yan Lai; Wei-Gang Qi; Yi-An Yao; Xue-Bo Liu
Journal:  World J Emerg Med       Date:  2014

2.  Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction.

Authors:  Shan-Shan Zhou; Feng Tian; Yun-Dai Chen; Jing Wang; Zhi-Jun Sun; Jun Guo; Qin-Hua Jin
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

3.  Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI.

Authors:  Wenbo Liu; Zhipeng Zou; Haipeng Jiang; Qiang Li; Fangming Guo; Zhen Wang; Hongguang Zhu
Journal:  Exp Ther Med       Date:  2016-11-18       Impact factor: 2.447

4.  No-reflow phenomenon and comparison to the normal-flow population postprimary percutaneous coronary intervention for ST elevation myocardial infarction: case-control study (NORM PPCI).

Authors:  Jennifer Ann Rossington; Eirini Sol; Konstantina Masoura; Konstantinos Aznaouridis; Raj Chelliah; Michael Cunnington; Benjamin Davison; Joseph John; Richard Oliver; Angela Hoye
Journal:  Open Heart       Date:  2020-07

5.  Impact of the Total Ischemia Time on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Mohamed Khalfallah; Amany Allaithy; Dina A Maria
Journal:  Anatol J Cardiol       Date:  2022-05       Impact factor: 1.475

6.  Relation of Angiographic Thrombus Burden with Severity of Coronary Artery Disease in Patients with ST Segment Elevation Myocardial Infarction.

Authors:  Hakan Duman; Mustafa Çetin; Murtaza Emre Durakoğlugil; Hüsnü Değirmenci; Hikmet Hamur; Mehmet Bostan; Zakir Karadağ; Yüksel Çiçek
Journal:  Med Sci Monit       Date:  2015-11-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.